This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by de la Vega, L. P. Articles by Kelly, D. G. Search for Related Content PubMed PubMed Citation Articles by de la Vega, L. P. Articles by Kelly, D. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMMONIUM OXALATE ASCORBIC ACID SODIUM ASCORBATE Medline Plus Health Information Home Care Services Social Bookmarking                         What's this?

Urinary Oxalate Excretion Increases in Home Parenteral Nutrition Patients on a Higher Intravenous Ascorbic Acid Dose

Lourdes Peña de la Vega, MD^*, John C. Lieske, MD^*, Dawn Milliner, MD^*, Janelle Gonyea, RD and Darlene G. Kelly, MD, PhD

From the ^* Mayo Clinic Hyperoxaluria Center and the Mayo Clinic College of Medicine and Division of Nephrology, Department of Internal Medicine, Department of Clinical Dietetics, and Division of Gastroenterology and Hepatology, Department of Internal Medicine, Rochester, Minnesota

Correspondence: Darlene G. Kelly, MD, PhD, Mayo Clinic, 200 First Street SW, Mayo West 19, Gastroenterology and Hepatology, Rochester, MN 55905. Electronic mail may be sent to kelly.darlene{at}mayo.edu.

Background: Vitamin C can be metabolized to oxalate. Case reports have suggested an association between IV vitamin C and urinary oxalate excretion. Recently, the US Food and Drug Administration required the dose of vitamin C in IV multivitamin preparations to be increased from 100 mg to 200 mg/d. We compared the urinary oxalate excretion level in stable home total parenteral nutrition (TPN) patients receiving both doses of vitamin C. Methods: Each participant provided a 24-hour urine sample for oxalate determination on the vitamin C dose (100 mg/d), and again after at least 1 month on the increased vitamin C dose (200 mg/d). A 2-day diet diary was completed covering the day before and the day of the urine collection and was analyzed for oxalate and vitamin C content. Comparisons were made using Student paired t test and Wilcoxon signed rank. Results: Thirteen patients (7 males/6 females) aged 63.1 ± 12.2 years who had no history of nephrolithiasis and had received TPN for 55.9 ± 78.8 months were enrolled. The most common indication for TPN was short bowel syndrome (38.5%). Eight patients had an intact colon. Urinary oxalate excretion increased on the 200-mg vitamin C dose, from 0.34 ± 0.13 to 0.44 ± 0.17 mmol/d (mean increase = 0.10 mmol/d; p = .04; 95% confidence interval 0.004 to 0.19 mmol/d). Oral intake of vitamin C and oxalate did not differ between the 2 collection periods. Conclusions: In therapeutically used doses, IV vitamin C increases urinary oxalate excretion, potentially predisposing susceptible individuals to nephrolithiasis. This factor should be considered in patients receiving home TPN.

Journal of Parenteral and Enteral Nutrition, Vol. 28, No. 6, 435-438 (2004)
DOI: 10.1177/0148607104028006435


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. P. Fuhrman Micronutrient Assessment in Long-Term Home Parenteral Nutrition Patients Nutr Clin Pract, December 1, 2006; 21(6): 566 - 575. [Abstract] [Full Text] [PDF]